These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28413978)

  • 21. Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) delta agonists.
    Bratton LD; Filzen GF; Geyer A; Hoffman JK; Lu G; Pulaski J; Trivedi BK; Unangst PC; Xu X
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3624-9. PubMed ID: 17498950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Peroxisome Proliferator-Activated Receptor Delta (PPARδ): A Medicinal Chemistry Perspective.
    Kadayat TM; Shrestha A; Jeon YH; An H; Kim J; Cho SJ; Chin J
    J Med Chem; 2020 Sep; 63(18):10109-10134. PubMed ID: 32539376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploring molecular fingerprints of selective PPARδ agonists through comparative and validated chemometric techniques.
    Nandy A; Roy K; Saha A
    SAR QSAR Environ Res; 2015; 26(5):363-82. PubMed ID: 25986170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome.
    Luquet S; Lopez-Soriano J; Holst D; Gaudel C; Jehl-Pietri C; Fredenrich A; Grimaldi PA
    Biochimie; 2004 Nov; 86(11):833-7. PubMed ID: 15589693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes.
    Luquet S; Gaudel C; Holst D; Lopez-Soriano J; Jehl-Pietri C; Fredenrich A; Grimaldi PA
    Biochim Biophys Acta; 2005 May; 1740(2):313-7. PubMed ID: 15949697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome.
    Li Z; Ren Q; Zhou Z; Cai Z; Wang B; Han J; Zhang L
    Eur J Med Chem; 2021 Dec; 225():113807. PubMed ID: 34455359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, and biological evaluation of novel dual PPARα/δ agonists for the treatment of T2DM.
    Ren Q; Deng L; Zhou Z; Wang X; Hu L; Xie R; Li Z
    Bioorg Chem; 2020 Aug; 101():103963. PubMed ID: 32480174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design, development and evaluation of novel dual PPARδ/PPARγ agonists.
    Gathiaka S; Nanayakkara G; Boncher T; Acevedo O; Wyble J; Patel S; Patel A; Shane ME; Bonkowski B; Wieczorek J; Rong Y; Huggins K; Smith F; Amin RH
    Bioorg Med Chem Lett; 2013 Feb; 23(3):873-9. PubMed ID: 23273519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and SAR of selective benzothiophene, benzofuran, and indole-based peroxisome proliferator-activated receptor delta agonists.
    Filzen GF; Bratton L; Cheng XM; Erasga N; Geyer A; Lee C; Lu G; Pulaski J; Sorenson RJ; Unangst PC; Trivedi BK; Xu X
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3630-5. PubMed ID: 17512197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Scintillation Proximity Assay (SPA)-Based Radioligand Binding for PPARα, PPARγ, and PPARδ Receptors.
    Grether U; Benz J; Hartung T; Roth D
    Methods Mol Biol; 2023; 2576():145-153. PubMed ID: 36152183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fine tuning of PPAR ligands for type 2 diabetes and metabolic syndrome.
    Ramachandran U; Kumar R; Mittal A
    Mini Rev Med Chem; 2006 May; 6(5):563-73. PubMed ID: 16719831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery and structure-based design of a new series of potent and selective PPARδ agonists utilizing a virtual screening method.
    Kato T; Ohara T; Suzuki N; Muto S; Tokuyama R; Mizutani M; Fukasawa H; Matsumura KI; Itai A
    Bioorg Med Chem Lett; 2022 Mar; 59():128567. PubMed ID: 35063634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold.
    Zhou Z; Cai Z; Zhang C; Yang B; Chen L; He Y; Zhang L; Li Z
    Bioorg Med Chem; 2022 Feb; 56():116615. PubMed ID: 35051813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic roles of peroxisome proliferator-activated receptor agonists.
    Staels B; Fruchart JC
    Diabetes; 2005 Aug; 54(8):2460-70. PubMed ID: 16046315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ligand- and structure-based drug design strategies and PPARδ/α selectivity.
    Maltarollo VG; Honório KM
    Chem Biol Drug Des; 2012 Oct; 80(4):533-44. PubMed ID: 22672760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
    Gross B; Staels B
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present).
    Lamers C; Schubert-Zsilavecz M; Merk D
    Expert Opin Ther Pat; 2012 Jul; 22(7):803-41. PubMed ID: 22697317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structural basis for specific ligation of the peroxisome proliferator-activated receptor δ.
    Wu CC; Baiga TJ; Downes M; La Clair JJ; Atkins AR; Richard SB; Fan W; Stockley-Noel TA; Bowman ME; Noel JP; Evans RM
    Proc Natl Acad Sci U S A; 2017 Mar; 114(13):E2563-E2570. PubMed ID: 28320959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and evaluation of a novel series of alpha-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome.
    Kasuga J; Yamasaki D; Araya Y; Nakagawa A; Makishima M; Doi T; Hashimoto Y; Miyachi H
    Bioorg Med Chem; 2006 Dec; 14(24):8405-14. PubMed ID: 16996742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery and structure-activity relationship study of 2-piperazinyl-benzothiazole derivatives as potent and selective PPARδ agonists.
    Kato T; Ohara T; Suzuki N; Naya N; Fukao K; Tokuyama R; Muto S; Fukasawa H; Itai A; Matsumura KI
    Bioorg Med Chem; 2023 Mar; 82():117215. PubMed ID: 36840990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.